Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma: Model development and external validation with Memorial Sloan Kettering Cancer Center model and the international metastatic renal cell carcinoma database consortium model.

Content Provider	Europe PMC
Author	Shin, Dongrul Jeong, Chang Wook Song, Cheryn Kang, Minyong Seo, Seong Il Kim, Jung Kwon Lee, Hakmin Chung, Jinsoo Hong, Sung-Hoo Hwang, Eu Chang Kwak, Cheol Park, Jae Young
Editor	Suman., Suman
Copyright Year	2021
Abstract	AbstractTo develop a new prognostic model for the overall survival of patients with clear cell metastatic renal cell carcinoma (mRCC) using Korean Renal Cancer Study Group (KRoCS) database and compared it with 2 renowned prognostic models: the Memorial Sloan Kettering Cancer Center (MSKCC) and the international metastatic renal cell carcinoma database consortium (IMDC) models.Data of 790 patients diagnosed with mRCC and receiving targeted therapy as their first-line treatment were pooled to this study. Data from 4 hospitals (n = 619) were used to develop the new model and those from other 5 hospitals (n = 171) were used for external validation. After detecting prognostic factors in multivariable Cox proportional-hazards regression analysis, patients were classified into 3 risk groups, favorable (0), intermediate (1–2), and poor (3 and more) by the number of prognostic factors.Seven variables such as more than 2 metastasis sites, no prior nephrectomy, Eastern Cooperative Oncology Group performance status ≥2, low hemoglobin, high serum corrected calcium, high neutrophil, high serum alkaline phosphatase were identified as prognostic factors for poor overall survival. Also, risk groups were categorized into 3 groups; median overall survival was 61.1 months in favorable, 26.5 months in intermediate, and 6.8 months in poor group. KRoCS ranked the first in all 3 statistical parameters including akaike information criterion (AIC), concordance index and generalized R2 among other prognostic models.We developed the KRoCS model and validated it externally with demonstrating its superiority over MSKCC and IMDC models. The KRoCS model can provide useful information for counseling patients with clear cell mRCC regarding life-expectancy.
ISSN	00257974
Journal	Medicine
Volume Number	100
PubMed Central reference number	PMC8341338
Issue Number	31
PubMed reference number	34397846
e-ISSN	15365964
DOI	10.1097/md.0000000000026826
Language	English
Publisher	Lippincott Williams & Wilkins
Publisher Date	2021-08-01
Publisher Place	Hagerstown, MD
Access Restriction	Open
Rights License	This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Subject Keyword	biomarkers kidney neoplasms prognostic factors renal cell carcinoma survival rate
Content Type	Text
Resource Type	Article
Subject	Medicine